Financials

Discussions Technicals Forecast Seasonals

4579 fundamentals

Overview Statements Statistics Dividends Earnings Revenue

Key facts

—

—

—

—

—

—

—

—

About

RaQualia Pharma, Inc. engages in a research and development of pharmaceuticals. Its medicines focus on pain, gastrointestinal, auto-immune diseases, inflammation, cancer, and Alzheimer's. Its products include Anidulafungin, Dalbavancin, Ziprasidone, 5-HT4 Partial Agonist, and 5-HT2B Antagonist. The company was founded on February 19, 2008 and is headquartered in Nagoya, Japan.

Valuation

Fundamental metrics to determine fair value of the stock

Summary

No data available

There's currently no market capitalization, revenue or net income data to show.

Valuation ratios

Growth and Profitability

Company’s recent performance and margins

Dividends

Dividend yield, history and sustainability

4579 does not pay dividends

The company has not previously paid dividends and at the moment there is no information about whether it is going to pay them in the future

Financial health

Financial position and solvency of the company